The Wyss Institute for Biologically Inspired Engineering at Harvard University and Sony DADC agreed to collaborate to harness Sony DADC’s global manufacturing expertise to further advance the Institute’s Organs-on-Chips technologies.

Human Organs-on-Chips are composed of a clear, flexible polymer about the size of a computer memory stick, and contain hollow microfluidic channels lined by living human cells. This allows researchers to recapitulate the physiological and mechanical functions of the organs, and to observe what happens in real time. The goal is to provide more predictive and useful measures of the efficacy and safety of new drugs in humans at a fraction of the time and costs associated with traditional animal testing.

“We are excited to apply Sony DADC’s deep manufacturing expertise to confront one of the major challenges in the life sciences by helping to accelerate the translation of the Wyss Institute’s Organ-on-Chips from the benchtop to the marketplace,” said Christoph Mauracher, senior vp of the biosciences division of Sony DADC. “The Organs-on-Chips have the potential to revolutionize testing of drugs, chemicals, toxins, and cosmetics.”

This collaboration builds on the momentum the Wyss Institute team has gained recently on its Organs-on-Chips research program, explained a Wyss Institute spokesperson. With support from Defense Advanced Research Projects Agency (DARPA), NIH, FDA, and pharmaceutical partners, more than ten Organs-on-Chips are currently under development at the Wyss Institute, including a lung, heart, liver, kidney, bone marrow, and gut-on-a-chip; there is also a major effort to integrate these organ chips into “human body-on-chips” that mimic whole body physiology.

In February, Wyss’s founding director, Don Ingber, M.D., Ph.D., who leads the Organs-on-Chips research program, received the prestigious 3Rs Prize from the U.K.’s National Centre for the Replacement, Refinement, and Reduction of Animals in Research for the lung-on-a-chip. This month, the Society of Toxicology awarded him the Leading Edge in Basic Science Award for his “seminal scientific contributions and advances to understanding fundamental mechanisms of toxicity.”

“Our work with Sony DADC is a wonderful example of the Wyss Institute model in action,” said Wyss’s founding director, Don Ingber, M.D., Ph.D., who leads the Organs-on-Chips research program. “We collaborate with industry to help de-risk the technologies we develop, both technically and commercially, and therefore expedite their translation into real-world applications.”

Previous articleBioserv and Advantar Target a Comprehensive Value Chain
Next articleGalena Buys Orexo’s Pain Drug for $10M+